请输入关键字:

热门搜寻:

Boehringer Ingelheim receives approval for Aservo® EquiHaler®, industry first therapy for severe equine asthma

日期:2020年2月4日 下午6:45

Aservo® EquiHaler® (ciclesonide inhalation solution) is a result of synergies between the company’s human pharma and animal health businesses.
The inhaler addresses an unmet need in the equine segment.
The company continues to set new standards of care to strengthen its commitment to animal welfare.

INGELHEIM, Germany--()--Horses with severe equine asthma struggle to breath, even at rest. Last week, the European Commission granted marketing authorization1 to Boehringer Ingelheim for the new Aservo® EquiHaler® - and horses that suffer from severe equine asthma can now benefit from this new therapy.

While inhaled therapies for the treatment of asthma are common in human health, the approval of the Aservo® EquiHaler® marks an industry first in equine medicine, as until now, there has been no approved corticosteroid inhalant therapy licensed for use in horses with severe equine asthma.

The Aservo® EquiHaler® represents the culmination of over a decade of collaboration between Boehringer Ingelheim’s human pharma and animal health R&D groups. The Respimat™ inhaler used in human respiratory disease is differentiated by the unique Soft Mist™ Technology, which was integrated into the new Aservo® EquiHaler®, allowing medication to be inhaled, deep into the lung. “The inhaler is a prime example of leveraging innovation efforts of both our businesses. This has been a strength in the past and we will expand this in the near future to further increase the delivery of innovative solutions for our patients and customers,” shares Eric Haaksma, Head of R&D, Boehringer Ingelheim Animal Health Business Unit.

The newly approved inhaler is designed specifically for use in horses. It includes an ergonomic handle and dosing lever for ease of user handling, and a nostril adaptor that fits gently inside the nostril of the horse, allowing the horses to easily inhale the medicated mist. The active ingredient in the Aservo® EquiHaler® is the prodrug ciclesonide, which is a corticosteroid that is activated directly in the lung, reducing lower airway inflammation associated with severe equine asthma.

“Treating severe equine asthma can be challenging for veterinarians and horse owners, who struggle to find safe and effective ways to help horses breath,” says Erich Schoett, Global Business Head of Equine for the Boehringer Ingelheim Animal Health Business Unit. “Bringing a new, safe and effective treatment to the market is something that we can really be proud of. It is a strong indicator of the commitment that Boehringer Ingelheim has to the health and welfare of horses, and to the investment that we make into continuing to advance therapies through collaboration and innovation.”

The Aservo® EquiHaler® is expected to be available for veterinarians in the EU in 2020.

For references and notes to editors, please visit: https://www.boehringer-ingelheim.com/press-release/approval-aservo-equihaler-equine-asthma-therapy

Boehringer Ingelheim receives approval for Aservo® EquiHaler®, industry first therapy for severe equine asthma

Contacts

Boehringer Ingelheim
Tereza Urbankova
Head of External Communication Animal Health
Boehringer Ingelheim Corporate Center GmbH
P: +49 6132 77-184817
tereza.urbankova@boehringer-ingelheim.com

财华网所刊载内容之知识产权为财华网及相关权利人专属所有或持有。未经许可,禁止进行转载、摘编、复制及建立镜像等任何使用。

如有意愿转载,请发邮件至content@finet.com.hk,获得书面确认及授权后,方可转载。

更多精彩内容,请登陆
财华香港网(https://www.finet.hk/)
财华智库网(https://www.finet.com.cn)

现代电视(http://www.fintv.hk)

相關文章

2月4日
关於採用TRIPLE-1、最先进7nm·5nm製程的2个新产品的发布
2月4日
FINEOS签下美国一级保险公司成为新客户
2月4日
香港会计师公会「穷小子、富小子」计划连续两届获「理财教育奖」
2月4日
新QP,通往会计康庄之路
2月4日
Crest View International报告称,亚马逊股价随Prime订户数量增加而飆升
2月4日
2020年诺贝尔奖得主黑格拉大会在沙乌地阿拉伯埃尔奥拉举行
2月4日
病人安全运动基金会号召临床医生、病人权益宣导者、医院和医疗技术公司支持2020年联邦卫生IT计画中的资料共享
2月4日
提供一贯有益的经验:全球调查资料显示,“Look Good Feel Better”活动对各种文化和地域均有影响力
2月4日
PMI Signposts报告强调全球气候变迁、基础设施革新等形势下的专案机会
2月4日
Teva发布AJOVY® (fremanezumab)日本临床试验头条阳性结果

视频

快讯

10:19
侨雄国际(00381.HK):委任段玉聪为人工智能实验室首席科学家
10:15
【异动股】券商概念板块拉升,同花顺(300033.CN)涨15.0%
10:05
越秀地产(00123.HK)10月合同销售同比上升约46.8%
10:00
【盈警】瑞森生活服务(01922.HK)料中期盈转亏不少于9000万元人民币
09:40
正荣地产(06158.HK)10月合约销售额约5.58亿元人民币
09:31
【异动股】医药商业板块低开,漱玉平民(301017.CN)跌5.21%
09:31
【异动股】气溶胶检测板块高开,禾信仪器(688622.CN)涨20.01%
09:31
【异动股】航天航空板块高开,晟楠科技(837006.CN)涨29.97%
09:23
央行公开市场净回笼3645亿元
08:47
沪深两市融资余额增加154.01亿元